Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay

References

• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–104.
   PubMed Web of Science ®Google Scholar
• Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620–2.
   PubMedGoogle Scholar
• Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012;59:C4480.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014;91:56–64.
   PubMedGoogle Scholar
• Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360–1.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Losi M, D’Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198–204.
   PubMed Web of Science ®Google Scholar
• Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37: 88–99.
   PubMed Web of Science ®Google Scholar
• Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63–75.
   PubMed Web of Science ®Google Scholar
• Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, et al. Interferon-γ release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011;23:377–84.
   PubMed Web of Science ®Google Scholar
• Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 2014;91:24–31.
   PubMedGoogle Scholar
• Mariette X, Baron G, Tubach F, Liote F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012;71:1783–90.
   PubMed Web of Science ®Google Scholar
• Jung YJ, Lyu J, Yoo B, Lee CK, Kim YG, Yang SK, et al. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment. Int J Tuberc Lung Dis 2012;16:1300–6.
   PubMed Web of Science ®Google Scholar
• Jung YJ, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG, et al. The ‘either test positive’ strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. Int J Tuberc Lung Dis 2014;18:428–34.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence (UK); 2011.
   Google Scholar
• Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, et al. Serial QuantiFERON TB-Gold In-Tube testing during LTBI therapy in candidates for TNFi treatment. J Infect 2013;66:346–56.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221–47.
   Google Scholar
• Steffen RE, Caetano R, Pinto M, Chaves D, Ferrari R, Bastos M, et al. Cost-effectiveness of Quantiferon-TB® Gold-In-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PloS One 2013;8:e59546.
   Google Scholar
• Kim SY, Jung GS, Kim SK, Chang J, Kim MS, Kim YS, et al. Comparison of the tuberculin skin test and interferon- gamma release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 2013;41: 103–10.
   PubMed Web of Science ®Google Scholar
• Scrivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri AR, Priori R, et al. Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 2012;31:1567–75.
   Google Scholar
• Pareek M, Bond M, Shorey J, Seneviratne S, Guy M, White P, et al. Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013;68:230–9.
   PubMed Web of Science ®Google Scholar
• Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, et al. A toolbox for tuberculosis (TB) diagnosis: an Indian multicentric study (2006–2008). Evaluation of QuantiFERON-TB Gold In Tube for TB diagnosis. PLoS One 2013;8:e73579.
   Google Scholar
• Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24–30.
   PubMed Web of Science ®Google Scholar
• Lai CC, Tan CK, Lin SH, Liao CH, Huang YT, Hsueh PR. Diagnostic performance of whole-blood interferon-gamma assay and enzyme-linked immunospot assay for active tuberculosis. Diagn Microbiol Infect Dis 2011;71:139–43.
   PubMed Web of Science ®Google Scholar
• Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, Ayles H, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002;16:2285–93.
   PubMed Web of Science ®Google Scholar
• Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001;183:469–77.
   PubMed Web of Science ®Google Scholar
• Higuchi K, Sekiya Y, Igari H, Watanabe A, Harada N. Comparison of specificities between two interferon-gamma release assays in Japan. Int J Tuberc Lung Dis 2012;16: 1190–2.
   Google Scholar
• Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011;18:2102–8.
   PubMed Web of Science ®Google Scholar
• Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter L, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med 2012;185:427–34.
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States,2010. MMWR Recomm Rep2010;59:1–25.
   PubMedGoogle Scholar
• Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK, Kim YG, et al. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. Respir Med 2013;107:1797–802.
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti- tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884–94.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site- specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368–76.
   PubMed Web of Science ®Google Scholar